


To provide long-term capital growth through investment mainly in ordinary shares in the US and Canada.
| Name | % Net Assets | 
|---|---|
| Exxon Mobil | 5.6% | 
| Microsoft | 3.5% | 
| Johnson & Johnson | 3.2% | 
| Pfizer | 2.5% | 
| Intel | 2.3% | 
| General Electric | 2.3% | 
| ConocoPhillips | 2.1% | 
| Monsanto | 2.0% | 
| Lilly (Eli) | 2.0% | 
| Medtronic | 1.9% | 
| Key | % Net Assets | 
|---|---|
| 5.6% | |
| 3.5% | |
| 3.2% | |
| 2.5% | |
| 85.2% | 
| Date | 20-Aug-2025 | 
|---|---|
| NAV | 1,583.00p | 
| Currency | GBP | 
| Change | -5.00p | 
| % | -0.31% | 
| YTD change | 75.00p | 
| YTD % | 4.97% | 
| Fund Inception | 15/10/1984 | 
|---|---|
| Fund Manager | Erik Rubingh | 
| TER | 0.79 (30-Apr-2011) | 
| Minimum Investment | |
|---|---|
| Initial | £500000 | 
| Additional | £25,000 | 
| Savings | n/a | 
| Charges | |
|---|---|
| Initial | 1.00% | 
| Annual Mang't | 0.75% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.02 | 
| Sharpe ratio | -0.03 | 
You are here: research